Why Scribe Therapeutics’ Share Is Plunging Despite ARK’s $4M Buy‑in
Sharp drop hits Scribe Therapeutics despite ARK Invest’s $4 M buy. Thin liquidity, 200‑day SMA miss and steep 1‑month decline signal caution for investors.
3 minutes to read
SCRIBE THERAPEUTICS INC